Sumitomo Dainippon Pharma Annual Report 2017

245.6North American MarketChinese MarketMaximize prots from existing productsEstablish highly efcient business foundationFurther growth in sales of atypical antipsychotic agent LATUDA® and antiepileptic APTIOM®Expand sales in the Chronic Obstructive Pulmonary Disease (COPD) area by launching new products(Billions of yen)(forecast)2014201520162017North American Market Net Sales148.2184.9197.9(Billions of yen)(forecast)2014201520162017Chinese Market Net Sales17.118.418.317.6NorthAmericaMEROPEN® (brand name in China: MEPEM®)IndicationsFeaturesGeneral infections, febrile neutropeniaStandard therapy for severe infections, used in many countriesBROVANA®IndicationsFeaturesChronic obstructive pulmonary disease (COPD)A long-acting beta-agonist, which is indicated for the long-term, twice-daily maintenance treatment of patients with COPD, including chronic bronchitis and emphysema.About targetdiseaseCOPD is characterized by persistent respiratory symptoms and airow limitation that is due to airway and/or lung abnormalities usually caused by signicant exposure to toxic particles or gases.Approximately 15.7 million adults in the U.S. report that they have been diagnosed with COPD. COPD is responsible for over 120,000 deaths per year, making it the third leading cause of death in the U.S.LATUDA®IndicationsFeaturesSchizophrenia, bipolar I depressionAn atypical antipsychotic with afnity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effectsAbout targetdiseaseSchizophrenia is a chronic, serious and often severely disabling brain disorder. Symptoms such as hallucinations and delusions usually start between ages 16 and 30. It affects approximately 2.4 million adults in the United States.Bipolar disorder is a mental health condition that is characterized by potentially debilitating mood swings, including periods of depression and mania. It affects approximately 12.6 million adults in the United States.APTIOM®IndicationsFeaturesPartial-onset seizures (Monotherapy / Combination therapy)APTIOM is the only exclusively once-daily, AED FDA-approved for use as monotherapy or adjunctive therapy for partial-onset seizures in adults.About targetdiseaseEpilepsy is the fourth most common neurological condition. In the U.S., approximately 2.9 million people are living with active epilepsy, including approximately 460,000 children aged 0 to 17 years.(FY)(FY)34Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#35